Aptamer Group Plc · LSE:APTA
Aptamer — H1 2022 Earnings Presentation
29 slides from Aptamer's earnings presentation, March 2022
Slide 1: Interim results for the 6 months ended 31/12/2021
Interim results for the 6 months ended 31/12/2021 Dr Arron Tolley Chief Executive Officer & Founder arron.tolley@aptamergroup.com Eleanor Brown (formerly Courtman-Stock) Chief Financial Officer eleanor.brown@aptamergroup.com Dr David Bunka Chief Technical Officer & Founder david.bunka@aptamergroup.c
Slide 2: Disclaimer
DISCLAIMER Private and Confidential - for personal use only and not for distribution This presentation (“Presentation”) contains forward-looking statements, including in relation to the financial position and prospects of Aptamer Group plc (“Company”) and its group (“Group”). These forward-looking s
Slide 3: Presentation team
Presentation team Dr Arron Tolley Eleanor Brown CEO CFO • Co-founded Aptamer Group in 2008 • Over 10 years in practice in Big Four • Globally-recognised technical & firms, gaining a wealth of knowledge commercial leader in aptamers & experience across multiple sectors • Delivered several patent-pend
Slide 4: Introduction to Aptamer Group
Introduction to Aptamer Group 1
Slide 5: Aptamers address the challenges facing antibodies and alternatives
Aptamers address the challenges facing antibodies and alternatives The antibody market is well established, but has well-known problems that are addressable with aptamers Value creating differentiating characteristics of aptamer affinity ligands Broader target applicability Lab based isolation of ap
Slide 6: The Optimer platform
® The Optimer platform Aptamer + • An Optimer® is the minimal aptamer sequence which retains the ability to bind to the target • Optimer® binders have a more stable structure than the parental aptamer which results in improved binding properties • Smaller molecular size (<15 kDa compared to ~30 kDa
Slide 7: USP: Automated high-throughput discovery platform
USP: Automated high-throughput discovery platform Tailored selection strategies, optimised for different target classes and applications, increases the potential for success in each Optimer® discovery campaign. • Teams of specialists, with distinct processes to address different target types (protei
Slide 8: Aptamers are applicable in multiple verticals within the life sciences
Aptamers are applicable in multiple verticals within the life sciences The aptamer platform technology has demonstrated long-term value generation in several key verticals in the life sciences market, with high value opportunistic diagnostic and therapeutic licensing and milestone-based deals Compet
Slide 9: Aptamer Group revenue model
Aptamer Group revenue model • Contract research services • Enabling Diagnostics • Enabling Therapeutics • Global research antibody market valued • Global diagnostic speciality antibodies • Global antibody therapeutic market at $3.6bn in 2020 market valued at $19.9bn in 2020 worth in excess of $114bn
Slide 10: Selected signed commercial contracts
Generating long-term value across key pillars of the life science market: Selected signed commercial contracts Customer Target / Area Requirement Commercials Vertical Emerging life science tool company Peptides High value R&D £3.8m development fee, with up to Research reagents £16m in licence fee an
Slide 11: Growth strategy to expand core capabilities & market share
Growth strategy to expand core capabilities & market share Underpinned by £10.8m IPO fundraise, Aptamer Group intend to accelerate growth and increase value capacity over multiple verticals to deliver more solutions and higher value engagements Scale-up & Automation Novel Nucleotide Chemistries Comm
Slide 12: Operational review
we °° ° °° °°» Operational review 3) aptamer
Slide 13: Key highlights for H1 2022
Key highlights for H1 2022 Aptamer Group • Raised gross proceeds of £10.8 million in conjunction with AIM listing on 22 December 2021 • Board appointments of Ian Gilham as Chairman and Angela Hildreth Aptamer Solutions • Contract secured with a top five global pharma company to develop Optimer® bind
Slide 14: Post-period end highlights
Post-period end highlights Aptamer Diagnostics • Optimer® binder to the SARS-CoV-2 Spike protein, developed using the Company's proprietary discovery and development platform, was proven to detect Omicron • Optimer®-enabled monitoring system installed at multiple UK sites as part of Environmental Mo
Slide 15: Post-IPO Progress: R&D
Post-IPO Progress: R&D • Work to integrate our novel nucleotide chemistry platform is underway. This will integrate 10 years of acquired development work, in the field of nucleotide chemistry, into a new platform called Optimer®+, which we believe will: • Broaden applications and improve the perform
Slide 16: Post-IPO Progress: Scaling capacity and expanding the team
Post-IPO Progress: Scaling capacity and expanding the team • Scaling of current Optimer® development platform to service expected demand • Scale-up includes expanding automation systems and increasing capacity of the current platform • Additional equipment is being purchased to remove process bottle
Slide 17: Financial review
we °° ° °° °°» Financial review @ aptamer
Slide 18: Financial highlights
Financial highlights • Revenue has increased by 183% to £1.4 million (H1 2021: £0.5m) as a consequence of the focus on revenue growth and the improvement in commercial traction, which has continued to date during H2 • Cash balance increased to £9.8 million (31 December 2020: £1.0 million, 30 June 20
Slide 19: Comprehensive income
Comprehensive income • Focus on revenue growth driving increased turnover; revenue has been generated from the provision of contract research services in all three business units • GPM has improved as a result of more capacity being filled; a large proportion of cost of sales is semi-fixed labour. H
Slide 20: Financial position
Financial position • Non-current assets – During H1 2022 the Company invested in capital equipment to remove some of the production bottlenecks; further improvements planned for H2 2022 as the placing proceeds are deployed to support further revenue growth. A new lease starting on 1 July 2021 create
Slide 21: Financial outlook
Financial outlook • The Group anticipates higher revenues in the second half of the year as many of the current development projects near completion and full invoicing can be recognised or secondary phases initiated • The second half of the financial year has already seen contracts signed with new a
Slide 22: Summary & outlook
we °° ° °° °°» Summary & outlook 3) aptamer
Slide 23: Delivering the next chapter
Delivering the next chapter • The strong growth in H1 2022 has reinforced that there is both market need and demand for aptamer technology to support innovation across the life science industry and that Aptamer Group has a clear, differentiated technology offering • Commercial traction building in E
Slide 24: Summary
Summary • Solve intractable problems for biotech and big pharma by Service level agreements and licence deals with developing aptamers, which are a disruptive technology with advantages large stakeholders across life sciences over antibodies • Disrupting the market with a proprietary, scalable autom
Slide 25: Appendix
we °° ° °° °°» Appendix
Slide 26: Intellectual Property: we protect our position
Intellectual Property: we protect our position We own approximately 75 patent rights (granted and pending) in various global territories. With 16 different patent families split across: novel aptamer-based diagnostic platforms, novel binding chemistries and specific aptamers against commercial targe
Slide 27: Building momentum with the Optimer platform
Building momentum with the Optimer® platform Development of specific Optimer reagents to the Targeting significant Major therapeutics co- agreed range of targets, Extension of strategic commercial contracts development partnership the Optimer® binders will collaboration with across all verticals wit
Slide 28: Board appointments
Board appointments • Board appointments of Ian Gilham as Chairman, and Angela Hildreth and Dr John Richards as Non-Executive Directors Dr Ian Gilham Dr John Richards Angela Hildreth Chairman NED NED • Former Non-Executive Chairman at • Expert in scale up and manufacture of • Finance Director at Futu
Slide 29: World renowned Scientific Advisory Board
World renowned Scientific Advisory Board Scientific Advisory Board Shozo Fujita Prof Paul Townsend Prof Rick Body SAB SAB SAB Additional members of the Executive Dean of the Faculty of Professor of Emergency Medicine • Expertise in aptamer development • Health and Medical Sciences and Pro • at the U